Results 211 to 220 of about 282,772 (364)

Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART‐FID

open access: yesEuropean Journal of Heart Failure, EarlyView.
Changes in serum phosphate levels over time with ferric carboxymaltose (FCM) in a randomized, double‐blind, prospective substudy of HEART‐FID assessing the following outcomes: serum phosphate, 1,25 dihydroxyvitamin D, 25‐hydroxyvitamin D levels and plasma levels of intact parathyroid hormone during 6 months subsequent to FCM infusion.
Nina Nouhravesh   +16 more
wiley   +1 more source

Influence of Renal Function on Phosphoramide Mustard Exposure: A Nonlinear Mixed‐Effects Analysis

open access: yesThe Journal of Clinical Pharmacology, Volume 63, Issue 1, Page 135-142, January 2023., 2023
Abstract Phosphoramide mustard (PM) is the final cytotoxic metabolite formed from the parent compound cyclophosphamide through a complex metabolic pathway, primarily through hepatic metabolism. Little is known about the effect of renal elimination on the disposition of PM.
Mutaz M. Jaber   +5 more
wiley   +1 more source

Relevance of residual tricuspid regurgitation for right ventricular reverse remodelling after tricuspid valve intervention in patients with severe tricuspid regurgitation and right‐sided heart failure

open access: yesEuropean Journal of Heart Failure, EarlyView.
Right ventricular reverse remodelling after transcatheter tricuspid valve intervention (TTVI). Optimal tricuspid regurgitation (TR) reduction is critical for right ventricular reverse remodelling. CMR, cardiac magnetic resonance; echo, echocardiography; RV EDV, right ventricular end‐diastolic volume. Abstract Aims Right ventricular reverse remodelling (
Ludwig T. Weckbach   +16 more
wiley   +1 more source

Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open‐Label, Single‐Dose, Parallel Group Study

open access: yesThe Journal of Clinical Pharmacology, Volume 63, Issue 2, Page 250-258, February 2023., 2023
Abstract Maribavir, an orally bioavailable antiviral, has shown superior activity against posttransplant cytomegalovirus infection compared with conventional antivirals. It is primarily metabolized in the liver. This open‐label, single‐center study evaluated the effect of hepatic impairment on the pharmacokinetics of maribavir in nontransplant ...
Ivy Song   +3 more
wiley   +1 more source

Corrigendum: Analysis on the MRI and BAEP results of neonatal brain with different levels of bilirubin

open access: yesFrontiers in Pediatrics, 2022
Zhongxing Lu   +4 more
doaj   +1 more source

Clinical evaluation of the installation conditions and accuracy of wearable neonatal jaundice meter. [PDF]

open access: yesSci Rep
Uozumi A   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy